United States: Amarin And FDA Agree To Landmark Settlement On Off-Label Promotion

Last Updated: March 17 2016
Article by Toni-Ann Citera, Michael A. Carvin, Laura F. Laemmle-Weidenfeld, Colleen Heisey, Karen P. Hewitt, Traci L. Lovitt, Rajeev Muttreja, Heather O'Shea and Stephen G. Sozio
Most Read Contributor in United States, September 2019

On March 8, 2016, Amarin Pharma, Inc. reached a noteworthy settlement in its lawsuit against the U.S. Food and Drug Administration ("FDA") to protect its First Amendment right to promote the drug Vascepa for nonapproved, off-label uses. Amarin Pharma, Inc. v. FDA (S.D.N.Y. No. 15-cv-3588) (Engelmayer, J.). Earlier, Judge Engelmayer had granted a preliminary injunction blocking the FDA from pursuing a misbranding suit against Amarin for the company's off-label promotion. This recent settlement now brings the litigation to a close—signaling a potential softening in the FDA's stance on off-label promotion and, potentially, a more active role for the courts in determining when off-label promotion is permitted.

Case Background

The FDA approved Vascepa (icosapent ethyl) capsules to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. The original approval was based on a single phase 3 clinical trial of patients with "very high" triglycerides, which was conducted under a Special Protocol Assessment ("SPA") agreement with the FDA. An SPA indicates FDA agreement that a study will support the approval of a drug product's application if the study is conducted in accordance with the protocol and achieves the agreed-upon objectives. Subsequently, Amarin designed and entered an SPA with the FDA to evaluate the effect of Vascepa on triglyceride levels among statin-treated patients with "persistently high" triglycerides (>200 and <500 mg/dL) in a single phase 3 clinical investigation. Amarin also agreed to conduct a cardiovascular outcomes trial on these patients.

Amarin submitted a supplemental application in February 2013, requesting FDA approval for use of Vascepa in patients with persistently high triglycerides. The application detailed the data from the studies conducted pursuant to the SPA, which met the primary endpoint, a significant secondary endpoint, and the obligations associated with the cardiovascular outcomes study. Often, SPA compliance leads to approval. Not here, however. Instead, the FDA seemed to have second thoughts about the underlying science. Specifically, the FDA did not feel the data sufficiently supported the drug's use in patients with persistently high triglycerides and rescinded the SPA, an extremely rare occurrence. In a Complete Response Letter, the agency stated that it needed additional data before it could approve the second use. It also warned Amarin that any effort to promote Vascepa for the unapproved use could constitute misbranding under the Food, Drug & Cosmetic Act.

Ten days after receiving the letter, Amarin sued the FDA. The company claimed that the First Amendment protected its right to tell doctors and other health care professionals about the data suggesting that Vascepa could be used to treat "persistently high" triglycerides. According to Amarin's complaint, the FDA's threat of a misbranding prosecution for the truthful, nonmisleading promotion of an off-label use had an impermissible chilling effect on the company's constitutionally protected speech. Amarin sought a preliminary injunction barring the FDA from pursuing such a claim.

The August 7, 2015 Ruling

In granting Amarin's motion for a preliminary injunction, Judge Engelmayer relied heavily on the U.S. Court of Appeals for the Second Circuit's ruling in United States v. Caronia. Caronia held that the First Amendment prohibited the government from criminally prosecuting an individual for the truthful, nonmisleading promotion of a drug for off-label uses. In Amarin's case, the government essentially sought to limit Caronia to its particular facts and procedural posture, focusing on improper instructions and other statements made to the jury there. But Judge Engelmayer read Caronia to more broadly disallow any and all misbranding prosecutions for truthful, nonmisleading off-label promotion, because, in the Second Circuit's view, the government lacked sufficient justification to prohibit such speech.

Judge Engelmayer then held that certain communications proposed by Amarin were indeed truthful and nonmisleading. For certain other communications, Judge Engelmayer provided revisions that would make the statements truthful and nonmisleading. But, he emphasized that his rulings were based only on the information before him: "A statement that is fair and balanced today may become incomplete or otherwise misleading in the future as new studies are done and new data is acquired."

Because Judge Engelmayer's ruling was only a decision on a motion for a preliminary injunction, it did not provide any final relief. In addition, the FDA was free to appeal to the Second Circuit. Shortly after the ruling was issued, however, Amarin and the FDA announced that they were discussing a potential settlement.

The March 8, 2016 Settlement

In the settlement—a stipulation that Judge Engelmayer has already approved—the government "agree[d] to be bound by the Court's conclusion that Amarin may engage in truthful and non-misleading speech promoting the off-label use of Vascepa ... and, under Caronia, such speech may not form the basis of a prosecution for misbranding." In addition, the government agreed that Amarin's proposed statements, as modified by the court's August 2015 ruling, were "truthful and non-misleading."

The settlement also sets forth a new procedure through which Amarin can seek preapproval of off-label promotional communications. In addition to the generally available FDA review procedures for promotional materials, Amarin may propose up to two communications per year about the off-label use of Vascepa to the FDA—allowing Amarin to reduce the risk that a particular communication would be seen as misleading. (Presumably, this process would be used for communications that do more than, for example, merely distribute a study published in a credible, peer-reviewed journal, where there would seem to be less potential for a dispute over the communication's propriety.) After receiving the proposed communication, the FDA has 60 days to respond with any concerns. If the parties cannot settle any disagreements on their own, either party may ask Judge Engelmayer to resolve the dispute. This special process will be in place through 2020.

Significance of the Settlement

The Amarin settlement is notable for at least two reasons. First, it may signal that the FDA is softening its approach to off-label promotion. In the settlement, the agency waived its right to appeal Judge Engelmayer's decision. Moreover, the settlement green-lighted not only the speech specifically approved by Judge Engelmayer but also all future "truthful and non-misleading" off-label promotion of Vascepa. This effectively endorses a broad reading of Caronia, which is something the government may have difficulty walking back.

That said, companies should proceed with caution: The settlement is, of course, an agreement with Amarin alone. And the settlement explicitly states that truthful and nonmisleading speech cannot be the basis for a misbranding prosecution "under Caronia," perhaps to preserve the government's ability to argue for a different result outside the Second Circuit (i.e., where Caronia is not binding). Still, this settlement should be useful to parties engaged in truthful and nonmisleading off-label promotion nationwide.

Second, the settlement provides that a court should resolve any disputes between Amarin and the FDA over whether proposed communications about off-label uses are permissible. This sort of ongoing judicial oversight is unusual. It remains to be seen whether other judges will have a similar appetite for such a role.

The settlement (like the First Amendment) protects only truthful and nonmisleading communications. As the settlement states, "Amarin bears the responsibility, going forward, of assuring that its communications to doctors regarding off-label use of Vascepa remain truthful and non-misleading." Given that new studies and new data can conceivably make older, once-proper communications misleading, Amarin's duty to make sure its communications "remain truthful and non-misleading" should not be taken lightly.

Nonetheless, by any measure, the Amarin settlement is a major milestone for the First Amendment's protection of truthful and nonmisleading off-label promotion.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions